The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy

NCT ID: NCT01795001

Last Updated: 2018-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

460 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2017-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fuchs' Endothelial Dystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

late-onset FECD

tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)

No intervention

Intervention Type OTHER

normal control

tissue samples from patients with normal corneas

No intervention

Intervention Type OTHER

non-FECD edematous control

tissue samples from patients with corneal edema but without FECD

No intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FECD
* normal corneas (including enucleations for uveal melanoma)
* non-FECD oedematous corneas

Exclusion Criteria

* prior irradiation therapy for uveal melanoma
* corneal extension of uveal melanoma
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fund for Scientific Research, Flanders, Belgium

OTHER

Sponsor Role collaborator

Funds for Research in Ophthalmology, Belgium

UNKNOWN

Sponsor Role collaborator

Mieke Perdaens fund for Eye Research

UNKNOWN

Sponsor Role collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joost J van den Oord, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

KU Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Translational Cell and Tissue Research - campus Sint-Raf - UZ Leuven

Leuven, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S55133

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CNGB1 and Allied Disorders
NCT04639635 RECRUITING
Saffron Supplementation in Stargardt's Disease
NCT01278277 UNKNOWN PHASE1/PHASE2